Improving the diagnosis of tuberculosis in children

42T, FIND, the global alliance for diagnostics, and Rutgers University (Rutgers) worked together to develop an innovative stool sample processing kit that has played a central role in informing the World Health Organization’s (WHO) recent policy update to improve the diagnosis of tuberculosis in children [ref 1].

In 2020, 1.1 million children fell ill with TB out of a total of around 10 million people worldwide. Although TB is treatable and preventable, it can be difficult to diagnose and treat in children [ref 2].

TB clinic waiting area — Mothers, children and babies waiting to be seen by TB medical staff outside a health centre in India. Photo credit: FIND / Ben Phillips

42T, Rutgers and FIND have successfully partnered to develop a simple, low-cost sample preparation kit, based on a design and process methodology first proposed by David Alland, director of the Public Health Research Institute at Rutgers University. Large-scale trials have shown the kit to be both effective and easy to use in a variety of settings. And we’re pleased that it has helped to inform the WHO in making its ground-breaking policy update on diagnosing childhood TB.

– Sarah Knight, head of healthcare technology at 42 Technology.

Diagnosing paediatric TB is a major challenge requiring fresh thinking, because traditional samples for TB testing just aren’t accessible from young children. Stool is so easy to collect from almost anyone – so being able to use that to test for TB is a major step forward. FIND was pleased to work with 42T and other partners to help generate crucial data for the WHO review, and we warmly welcome the update to the guidelines.

– Morten Ruhwald, Head of TB at FIND.

Diagnosis

TB is usually diagnosed using respiratory samples such as sputum, a nasal wash or sampling of stomach contents. But these are unpleasant, invasive procedures and where it is often difficult to get samples from children at all. Stool is the ideal non-invasive sample but it requires extensive pre-processing before it can be analysed using highly-sensitive PCR tests.

The easy-to-use SPK has been designed to effectively process stool samples without the need for any specialist laboratory equipment or technical skills. It works in conjunction with the Cepheid Xpert MTB/RIF Ultra assay, which was co-developed by David Alland’s team at Rutgers, FIND and others, and has been repeatedly endorsed by the WHO for offering improved diagnosis for detecting TB in adults and children [ref 4].

Lab technicians using a GeneXpert machine in a research laboratory in India. Photo credit: FIND / Ben Phillips

What we did

42T’s design and development inputs for the SPK project included: working closely with Rutgers to help test out key device functions, to design prototype moulded devices, and to transfer the final designs into volume manufacture to produce initial quantities for use in clinical trials. This work was also supported by a grant from the US National Institute of Allergy and Infectious Diseases.

42T and FIND have worked together on multiple long-term joint development projects over the last 10 years. 42T was specifically brought in for its creative approach in helping to solve complex and interrelated design problems that often occur when developing new diagnostics in readiness for private and public sector launch. The work has covered the development of diagnostics for TB, malaria and other diseases of the developing world.

If you would like to find out more please contact Sarah Knight:
sarah.knight@42T.com | +44 (0)1480 302700 | www.linkedin.com/in/sarah-knight1